.svg)
.svg)
On October 22-25, Ascendia will participate in the 2023 AAPS PharmSci360 Event at the Orange County Convention Center in Orlando, FL.
Ascendia Pharmaceuticals®, a leading specialty CDMO with a decade of proven formulation solutions, is excited to announce that we will be attending and exhibiting in Booth #2304 at the upcoming AAPS PharmSci360 event from October 22-25 in Orlando, FL. A number of our business development team members will be on-hand to discuss how our BEST philosophy and nanotechnologies make us well suited to be a CDMO partner of choice for your projects. Our scientists are ready to overcome your most difficult drug development challenges that require expertise in development and manufacturing of sterile or non-sterile products, oral solids, injectables, vaccines, or gene therapies.
Ascendia’s contingent includes Shaukat Ali, PhD, Senior Director of Scientific Affairs and Technical Marketing. We are proud to announce Dr. Ali is among those selected for elevation to AAPS Fellow status in recognition of his superior impact in fields relevant to AAPS’ mission of “Advancing the capacity of pharmaceutical scientists to improve global health.”
AAPS Fellows are nominated by AAPS Fellow members. The status of Fellow denotes professional excellence and a sustained, positive impact on global health and the AAPS community. The new Fellows will be formally inducted at during the Plenary Session at PharmSci 360 on Sunday, October 22.
For more information of the AAPS Fellows Program, please click here.
Shaukat Ali, PhD has had a long career firmly grounded in pharmaceutical science. His highlights include 53 publications, a book chapter, and nine trade journal articles. His article, “Combining HME & Solubilization: Soluplus® – The Solid Solution,” which appeared in Drug Delivery Technology in 2010, is so significant, that it has been cited more than 100 times despite appearing in trade media. He is also the Editor-in-Chief of the Journal of Analytical and Pharmaceutical Research. Hehas a total of 32 patents and patent applications. He He is the recipient of IPEC Foundation’s 2020 Henk de Jong Industrial Research Award for his significant contributions in the field of excipient technologies. He is a member of the USP Council of Experts and a co-chair of the Excipient Test Methods Expert Committee. He is also a co-chair of the AAPS Lipid Community.
Dr Ali joined Ascendia Pharmaceuticals in 2022 as part of our leadership expansion and has been instrumental in our continued growth – especially in the field of lipid nanoparticles. He has held several key roles within the industry with increasing responsibilities in areas of synthesis, formulations, and drug development. His expertise in excipients and innovative solubilization technologies – including amorphous solid dispersions, lipid-based self-emulsifying drug delivery systems (SEDDS), and nanoparticles for orals and liposomes for parenteral delivery – has led to the development and marketing of a many poorly soluble drug molecules. He has worked as a technical expert with a number of biopharma, ethical, and generic pharma companies in his career, and we have enjoyed working with him as a valued member of the Ascendia Pharmaceuticals team!
Your CDMO Partner
Dr. Ali and the Ascendia® team a will be available throughout AAPS. Our proprietary nanotechnologies and expanded manufacturing capability position us as a CDMO partner who can meet your timeline, budget, and technical requirements for current and future drug development projects.
If you have any questions for Dr. Ali or any other member of our team headed to Orlando, please take a moment and request a meeting with us during the upcoming AAPS PharmSci360 event!
